Search PubMed⌕ Search

Biomedical subjects

S Hellman

Publications and source records attributed to S Hellman.

At least 199 records · Page 11Linked to original sources
PubMed1976

Can pelvic irradiation be omitted in patients with pathologic stages IA and IIA Hodgkin's disease?

From April 1969 to December 1973, 81 unselected laparotomy-staged IA and IIA patients with supradiaphragmatic Hodgkin's disease were treated at the Joint Center for Radiation Therapy. Mantle and para-aortic fields alone were treated to 3600-4000 rads. Median follow-up was 31 months. There were six relapses including three true recurrences, two extensions, and one extra-nodal dissemination. Relapses were not related to histologic type. There were no pelvic or inguinal extensions. Disease-free survival was 95% in stage IA patients and 86% in stage IIA patients. Only one patient died of disease, with an overall survival of 96%. These results indicate that mantle and para-aortic irradiation is sufficient treatment for pathologic stage I and IIA supradiaphragmatic Hodgkin's disease. Such treatment obviates the need for pelvic irradiation or combination chemotherapy without compromising the success of treatment.

Adolescent↗
PubMed1976

The dentist and preventive dental health information.

Patients receive differing amounts of preventive dental health information from their dentist. What factors affect the amount of preventive information a patient receives? Many possible reasons which have been advanced for this difference are discussed in this paper. Using the clues presented in the literature, and results of a presurvey, some factors thought to influence the amount of preventive dental health information the patient receives were investigated. Specifically, the research problem was, "What is the relationship between the amount of preventive dental health information a patient receives from the dentist in his private office and the following factors: patient's appearance, interest-responsiveness, nervousness, need for dental care, request for service, orientation to dentistry, and dentist's liking for the patient?" The hypothesized relationships of amount of preventive dental information delivered to dentist's perception of patient's characteristics were not upheld. The paper tentatively concludes that the characteristics of the dentist and his dental practice affect the preventive information delivered more significantly than patient characteristics.

Anxiety↗
PubMed1975

Radiation as primary treatment for local control of breast carcinoma. A progress report.

One hundred patients with localized breast carcinoma have been treated by radiation alone from July 1, 1968, until June 30, 1973, at the Joint Center for Radiation Therapy. Patients were referred for many reasons, including changing opinions as to the indications for mastectomy. External beam therapy to the tumor bearing volume and its regional nodal chains has been frequently supplemented by iridium 192 interstitial implantation. Local control has been excellent, particularly in early stage disease. Regionally advanced mammary carcinoma, despite apparently adequate local therapy, demonstrates a rapidly falling survival curve, suggesting the need for early systemic chemotherapy.

Adenocarcinoma↗
PubMed1975

Radionuclide immunoglobulin lymphangiography: a case report.

Iodine-131-labeled immunospecific gamma globulin derived from immunization of rabbits with F antigen, a tumor associated antogen in Hodgkin's disease, has been utilized for intralymphatic infusion in a patient with known recurrent Hodgkin's disease inthe inguinofemoral and pelvic regions. Rectilinear scanning successfully delineatedthe tumor masses, and external monitoring showed retention of activity in the tumor sitesover an 8-day period.

Adult↗
PubMed1975

The treatment of non-Hodgkin's lymphoma.

Much of the approach to evaluation and management of the non-Hodgkin's lymphomas has been modeled after Hodgkin's disease. However, as the name implies, they are quite different. The non-Hodgkin's lymphomas are a group of diseases and syndromes. These many different presentations, syndromes, and possibly different diseases must be distinguished and separated in order to evaluate results. Advances in pathologic classification attempting to relate the disease to physiological activities of lymphocytes are being made, but a simple, clinically relevant scheme is not available at present. We recognize large differences in nodular vs. diffuse histologic patterns. Non-Hodgkin's lymphoma is only infrequently restricted to a single anatomical area, but when it is, radiation therapy can result in a significant proportion of cures. More widespread disease requires systemic therapy. Most encouraging results are found with whole-body radiation used as a systemic agent with the use of multidrug combination chemotherapy. Perhaps whole-body radiation will be most useful when combined with combination chemotherapy as systemic therapy for some groups of non-Hodgkin's lymphoma.

Cyclophosphamide↗
PubMed1975

Cell kinetics, models, and cancer treatment--some principles for the radiation oncologist.

The radiation oncologist must attempt to apply the developments in the laboratory to the clinical situation in a manner that will result in a therapeutic gain. The possible influences of radiation fractionation and protraction, cell renewal and recruitment of normal or tumor tissues, differences in acute and late radiation effects and possible chemotherapy-radiation interactions are all factors that can affect the ultimate result. In order to develop a therapeutic gain, the effect on the tumor must be greater than on the normal tissues.

Cell Division↗
PubMed1975

Advanced lymphosarcoma treated by total body irradiation.

Twenty-five cases of clinical Stage III and Stage IV lymphosarcoma primarily treated by total body irradiation (TBI) are reported. Fifteen cases demonstrated nodular histology and 10 demonstrated diffuse histology by the Rappaport criteria. Treatments were 15 rad given twice weekly, calculated to midpelvis, to a total dose of 150 rad. Toxicity was confined to thrombocytopenia, one-third of patients requiring interruptions in the treatment course to allow platelet count recovery. Five patients had additional local irradiation. Complete responses were seen in 80% of patients and partial responses in 20%. Sixteen patients (64%) have been in continuous, unmaintained remission since treatments for variable periods to 39 months. Of 9 patients with clinically recurrent disease, 3 received further TBI and are in remission, 3 are in remission on chemotherapy, one patient has died, failing on all therapy, and 2 have not been treated. One patient died of pneumonia at 12 months, without clinical evidence of disease. Overall, actuarial survival is 87% at 2 years and compares well with survival in a sequential combination drug treated group of patients matched for age, sex, and histology, though differences are not statistically significant in these small groups. Total body irradiation is an effective systemic agent in the management of advanced lymphosarcoma and should be considered in treating this disease.

Female↗